- Trial Phase
- Approved
- Time to Market
- Already approved and on the market since August 2019
- Why 4/10
- No PDUFA or pivotal-readout catalyst is scheduled within the next ~12 months because Barostim is already FDA-approved and commercialized. The next hard, dated binary catalysts are quarterly earnings (e.g., Q3 2026 report ~Nov 2026). As a single-product company, commercial execution is central to the thesis, but quarterly sales reports are not binary regulatory events. Per the impact rubric, an approved product with no pending regulatory decision scores 3-5.
Watch quarterly Barostim implant volumes and revenue growth as the key commercial-health proxy. With no pending PDUFA or pivotal readout, the stock's next catalysts are earnings reports and any CMS/private-payer coverage expansions. The wide analyst target range ($3.50–$6.00) highlights deep uncertainty around adoption trajectory.
Price Chart
Executive Summary
Barostim is CVRx's FDA-approved implantable baroreflex activation therapy (BAT) device for NYHA Class III heart failure. Already approved since 2019 and commercially marketed, Barostim is CVRx's sole product. The stock has fallen ~76% from its 52-week high of $11.30 to ~$2.83, reflecting slow commercial uptake and ongoing operating losses (Q1 2026 EPS -$0.50). Analysts see ~59% upside to a $4.58 mean target but the stock is deeply out of favor. Insider buying and some institutional accumulation (Renaissance, UBS, JPMorgan) provide bull signals, but the company has no near-term binary catalyst and faces the classic challenge of driving physician adoption and reimbursement for a novel surgical heart-failure therapy.
How It Works
Barostim is an implantable device that electrically stimulates the carotid baroreceptors (natural blood-pressure sensors in the neck). This triggers the body's baroreflex, which signals the brain to reduce the sympathetic nervous system output, leading to lower heart rate, relaxed blood vessels, and reduced workload on the failing heart. The device consists of an electrode placed near the carotid sinus connected to a small generator implanted under the collarbone (like a pacemaker).
Trial Status
Barostim received FDA Premarket Approval (PMA) in August 2019 for NYHA Class III heart failure with reduced ejection fraction. It is commercially available and implanted at hospital centers. The company continues to build clinical evidence, including post-market studies and investigator-initiated trials for expanded indications.
The Two-Sided Case
Upcoming Catalysts
- Quarterly earnings reports (next: Q3 2026, typically early November) with Barostim implant volume and revenue updates
- Any CMS or private-payer coverage policy expansions for Barostim therapy
- Potential label expansion data from ongoing/planned clinical studies
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CVRx, Inc. 8-K CVRX ·Originating report